Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-22 of 22 for your search:
Cancer Type/Condition:
Non-Hodgkin lymphoma, child
Stage/Subtype:
stage III childhood anaplastic large cell lymphoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
2.
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP23573-07-110
, SUN08-01, NCT00704054
3.
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years and younger
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-04083-L
, OHSU-IRB-248, NCT00238433
4.
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years old and under
Sponsor:
NCI
Protocol IDs:
CCCWFU-29506
, CCCWFU 29506, NCT00453206, CCCWFU-IRB00001366
5.
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
2 and over
Sponsor:
NCI
Protocol IDs:
CHNMC-06141
, 06141, NCT00589563
6.
Unrelated Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-2239.00
, 6722, FHCRC-IR-6722, NCT00723099
7.
Early Administration of Antithymocyte Globulin Followed By Cyclophosphamide, Busulfan, and Fludarabine Before a Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Kidney Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
75 and under
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
BMTGG-NSH-807
, NSH 807, NCT00787761
8.
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0604)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
1 to 70
Sponsor:
NCI, NHLBI
Protocol IDs:
606
, U01 HL069294, NCT00864227
9.
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
P2 L-D AB
, NCT00917826
10.
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
0 to 65
Sponsor:
Other
Protocol IDs:
2009-0266
, NCT01010217
11.
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
0 to 26
Sponsor:
Other
Protocol IDs:
CHNY 525
, AAAB2879, NCT01049854
12.
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
CHNY-02-516
, IRB# AAAB3095, NCT01050439
13.
Bevacizumab and AZD2171 in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
15 and over
Sponsor:
NCI
Protocol IDs:
MDA-MDACC-2005-0910
, MDACC 2005-0910, 7534, NCT00458731
14.
Ipilimumab in Young Patients With Advanced or Refractory Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0007
, 08-C-0007, NCI-P6068, 7458, NCT00556881
15.
T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Lymphoma, Lymphoepithelioma, or Severe Chronic Epstein-Barr Virus Infection Syndrome
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
BCM-H-9936-ALCI
, H 9936, NCT00671164
16.
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and under
Sponsor:
Other
Protocol IDs:
NKHEM
, NCT00697671
17.
Doxil, Bevacizumab and Temsirolimus Trial
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
12 and over
Sponsor:
Other
Protocol IDs:
2008-0384
, NCT00761644
18.
Study of Temsirolimus, Topotecan, and Bortezomib
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2008-0425
, NCT00770731
19.
Sirolimus and Cetuximab in Advanced Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2009-0226
, NCT00940381
20.
Infusion of Expanded Cord Blood T Cells
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
6 months to 55 years
Sponsor:
Other
Protocol IDs:
2006-0075
, NCT00972101
21.
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2009-0521
, NCT01015222
22.
T-cell Recovery in Patients With Leukemia, Advanced Lymphoma, Myelodysplastic Syndrome, or Myeloproliferative Disorder Receiving Alemtuzumab and Undergoing Donor Stem Cell Transplant
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
BCM-H-21079
, H-21079, BCM-REGALE, NCT00647010
Select All on Page
Help with Results
